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HCV NS5A Inhibitors Disrupt Replication Factory Formation:
A Novel Mechanism of Antiviral Action
See “Daclatasvir-like inhibitors block early
biogenesis of hepatitis C virus-induced
membranous replication factories independent
of RNA replication,” by Berger C, Romero-Brey I,
Radujkovic D, et al, on page 000.
In recent years, progress in the development of effec-tive antivirals to treat chronic hepatitis C virus (HCV)
infection has accelerated enormously. For more than a
decade the standard of care therapy for HCV was a combi-
nation of pegylated interferon-a and ribavirin (pegIFN-a/
RBV) for 24-48 weeks. Unfortunately this treatment
regimen is associated with only moderate efﬁcacy (50%-
80% sustained virologic response rates) and severe side
effects. However, as a result of the efforts of academic and
industry research groups and advances in our understand-
ing of the HCV life cycle, made possible by reliable cell
culture systems, numerous promising direct-acting antivi-
rals are in advanced stages of clinical development or have
already been approved. The addition of ﬁrst-generation
NS3/4A protease inhibitors, telaprevir and boceprevir, to
pegIFN-a/RBV therapy signiﬁcantly improved sustained
virologic response rates for genotype 1 infections.1,2 Like-
wise, the recent approvals of the second-wave NS3/4A
protease inhibitor simeprevir,3 and the highly effective
nucleotide analog inhibitor of the viral NS5B polymerase,
sofosbuvir,4 brings closer the goal of a safe, effective, all-
oral, and IFN-free direct-acting antiviral combination ther-
apy in the near future. Along with molecules that target
NS3/4A and NS5B, potent inhibitors of the viral NS5A
phosphoprotein will likely be important components of
future direct-acting antiviral combination therapies. Indeed,
the ﬁrst-in-class NS5A inhibitor daclatasvir (DCV) and
structurally related NS5A inhibitors ledipasvir and ombi-
tasvir are in the ﬁnal stages of clinical development for
use in various combinations, and a number of second-
generation NS5A inhibitors with higher genetic barriers to
resistance (eg, ACH-3102, MK-5172, and GS-5816) are in
earlier stages of clinical development. NS5A has no known
enzymatic activity and to date the exact mechanism(s) of
action of these inhibitors and indeed the exact functions of
NS5A remain unclear. In this issue of Gastroenterology,
Berger et al5 report that NS5A inhibitors interact with NS5A
and block formation of the “membranous web” (MW) that
houses HCV RNA replication, independent of effects on HCV
RNA replication. Furthermore, the authors present evidence
that DCV derivatives interact with NS5A dimers and
moderately impair functional interaction of NS5A with
phosphatidylinositol-4 kinase IIIa (PI4KIIIa) that stimulates
local accumulation of PI4-phosphate (PI4P) at sites of HCV
RNA replication. Together this study sheds new light on the
mechanisms of action of this unique and extraordinarily
potent class of antivirals.
Given its essential roles in multiple aspects of the HCV
life cycle, NS5A is an attractive and unique target of antiviral
therapy for chronic HCV infection. Since the identiﬁcation of
DCV (formerly BMS-790052) as a potent, pangenotypic in-
hibitor of HCV RNA replication,6 a number of studies have
investigated the potential mechanism(s) of action of DCV
and structurally related NS5A inhibitors. Collectively, these
studies have identiﬁed several inhibitor properties that may
explain their efﬁcacy (Figure 1B; reviewed in7–9). First, their
remarkable potency (picomolar to low nanomolar median
effective concentration values) suggests that these in-
hibitors may synergistically disrupt multiple functions of
NS5A in the HCV life cycle and/or target essential events in
establishment of replication sites that in time will prevent
continued HCV RNA replication. Second, the location of
resistance mutations in domain I of NS5A (namely sub-
stitutions at L31 and Y93; Figure 1A) indicate that domain I-
associated functions are speciﬁcally targeted. In this context,
the class-deﬁning resistance site Y93 is located at opposing,
membrane-proximal surfaces of the dimer interface for both
“back-to-back” and “clam-like” alternative domain I (geno-
type 1b) crystal structures.10,11 Third, biotin-tagged DCV
derivatives enable precipitation of NS5A from pretreated
HCV replicon-harboring cells,6,12 although interestingly fail
to precipitate NS5A from replicon lysates or pretreated
NS5A-overexpressing cells.12 In this context, it is note-
worthy that preformed replication complexes (RCs) are re-
fractory to inhibition of HCV RNA replication by NS5A
inhibitors.12–14 Furthermore, NS5A inhibitors have been
shown to induce redistribution of NS5A from endoplasmic
reticulum-derived foci,12–14 possibly to lipid droplets,12 and
limit hyperphosphorylation of NS5A,14–16 although these
effects may be indirect. Finally, it has been suggested that
NS5A inhibitors may disrupt interactions of NS5A with HCV
RNA, other viral proteins, and/or host factors that are
coopted by NS5A during the HCV life cycle. The study of
Berger et al5 comprehensively addresses many of these
properties of NS5A inhibitors and uniquely addresses their
effects on NS5A-induced PI4P accumulation and HCV-
induced membrane rearrangements.
Initially, Berger et al5 demonstrate that DCV derivatives
display potent antiviral activity against established HCV
RNA replication and particularly pronounced inhibitory ef-
fects on the early establishment of HCV RNA replication and
production of infectious virus. This is consistent with the
recent, elegant kinetic studies from McGivern et al,17 who
provided evidence that NS5A inhibitors target newly form-
ing RCs and early events in virus assembly. Next, the au-
thors use NS3-5B protein expression systems, that mirror
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virus-encoded NS protein expression uncoupled from HCV
RNA replication, to demonstrate that neither NS5A stability
nor NS5A dimerization are altered by DCV derivatives.
Interestingly, analysis of NS5A dimerization in the context of
NS3-5B polyprotein expression required the generation of a
viable “tandem NS5A” cassette that encoded differently
tagged NS5A proteins, because dimerization “in trans” was
not detectable. This suggests that NS5A dimerization may be
compartmentalized and/or tightly coupled to polyprotein
translation/cleavage.
Next, the authors demonstrate that a biotin-tagged NS5A
inhibitor enables precipitation of NS5A from cells that ex-
press the NS3-5B polyprotein and that inhibitor-mediated
NS5A precipitation is impaired (w30%) in the context of
Figure 1. Disruption of
virus-induced replication
compartment formation
by NS5A inhibitors. (A)
NS5A is composed of 3
domains (domains I, II, and
III) separated by low-
complexity sequences
(LCS). An amphipathic he-
lix (AH) at the amino (N)
terminus within Domain I
dictates anchorage of the
protein to endoplasmic
reticulum-derived mem-
branes. Numbers refer to
amino acid positions in
NS5A from the JFH-1
isolate. (B) Sites of NS5A
inhibitor action. NS5A in-
hibitors appear to (i) block
double membrane vesicle
(DMV) biogenesis and (ii)
inhibit functional interac-
tion of NS5A with PI4KIIIa
that otherwise stimulates
local production of PI4P.
However, NS5A inhibitors
have no signiﬁcant effect
on (iii) NS5A stability or (iv)
NS5A dimerization, but (v)
may disrupt formation of
higher order NS5A multi-
mers. Other consequ-
ences of inhibitor binding
include disruption of virus
particle assembly, inhibi-
tion of NS5A hyperpho-
sphorylation (potentially
indirect), and likely impair-
ment of the interactions of






































































































































the Y93H resistance mutation. This reduced binding is
suggested to contribute to the 750- to 1,000-fold increase in
NS5A inhibitor resistance associated with the Y93H substi-
tution. As described, molecular docking studies show that
DCV likely binds to membrane-proximal surfaces of both
“back-to-back” and “clam-like” dimer structures, to poten-
tially perturb the folding and/or ﬂexibility of the linker re-
gion between the N-terminal amphipathic helix and domain
I and in turn alter NS5A multimerization, membrane asso-
ciation, and/or interaction with viral or host RC compo-
nents. In this context, Berger et al5 demonstrate that DCV
derivatives moderately impair interaction of NS5A with
PI4KIIIa at very high inhibitor concentrations, but signiﬁ-
cantly inhibit HCV-induced PI4P accumulation in a dose-
dependent manner. Importantly, this effect was not
observed in the context of the Y93H resistance mutation.
This suggests that NS5A inhibitors disturb the functional
interaction of NS5A with PI4KIIIa in a similar manner to a
class of experimental mutations in NS5A that also limit PI4P
accumulation and inhibit HCV RNA replication and NS5A
hyperphosphorylation.18 Although inhibitor-mediated
disruption of functional NS5A-PI4KIIIa interaction may
contribute to the anti-HCV properties of these inhibitors, it
is possible that this effect is one of several consequences of
inhibitor-dependent disruption of the overall structure and/
or ﬂexibility of NS5A. In line with this, other important in-
teractions of NS5A with host factors (VAP-A, VAP-B, ANXA2,
oxysterol binding protein, etc) may also be directly or
indirectly disrupted by inhibitor binding. Furthermore,
because NS5A hyperphosphorylation is regulated directly or
indirectly by PI4KIIIa,18 inhibitor binding may alter the
accessibility of NS5A phosphoacceptor sites to this and
other kinases and shift the balance between alternative
NS5A phosphoforms (and possibly dimer conformations)
that are otherwise regulated by a cascade of phosphoryla-
tion events.19
Arguably, the most intriguing ﬁndings of this study are
the striking effects of DCV derivatives on the HCV-induced
MW and, speciﬁcally, the biogenesis of double membrane
vesicles (DMVs) that are the presumed sites of efﬁcient HCV
RNA replication.20–22 Ultrastructural studies revealed that
inhibitor treatment signiﬁcantly reduces the size and fre-
quency of DMVs resulting from NS3-5B polyprotein
expression or productive HCV infection and completely
blocks the biogenesis of DMVs in the context of early in-
hibitor treatment and NS3-5B polyprotein expression.
Importantly, these effects were absent or limited in the
context of the Y93H NS5A inhibitor resistance mutation.
Although it was initially considered that oligomerization
of NS4B was largely responsible for HCV-induced mem-
brane rearrangements, a recent study has revealed that a
concerted action of the nonstructural proteins (NS3-5B) is
required for normal MW formation and that NS5A, in
particular, is responsible for DMV formation.22 How might
NS5A mediate DMV formation and how might NS5A in-
hibitors disrupt this function? Although a number of models
for formation of HCV DMVs from endoplasmic reticulum
membranes have been proposed,22 it is not clear exactly
how NS5A participates. Strong evidence indicates that
recruitment and activation of PI4KIIIa by NS5A and sub-
sequent PI4P enrichment contributes to morphologically
normal MWs.23 Similarly, a recent study revealed that
enrichment of cholesterol in these membrane microdomains
by the PI4KIIIa effector oxysterol binding protein is also
essential to MW integrity.24 As NS5A expression alone in-
duces DMV formation,22 it may also participate more
directly in membrane rearrangements beyond roles in
enrichment of PI4P and cholesterol. It is possible that the
alternative dimer forms of NS5A coexist and form a super-
helical polymer, as suggested by Love et al,10 such that
membrane bending during DMV formation is the result of
membrane anchorage of NS5A by its N-terminal amphi-
pathic helix and NS5A oligomerization. The presence of
inhibitor-bound NS5A molecules could “lock” a particular
dimer form, prevent NS5A oligomerization, and/or distort
NS5A oligomers to disrupt DMV formation and ultimately
prevent de novo formation of functional RCs.
Taken together, this work from Berger et al5 provides a
signiﬁcant advance in our understanding of the mechanisms
of action of NS5A inhibitors and a new paradigm in antiviral
therapy. With NS5A inhibitors as an example, therapeutic
targeting of virus-induced membrane rearrangements for
other positive-strand RNA viruses could provide an addi-
tional, potent approach to antiviral drug development that
complements traditional targeting of viral enzymes.
Q3NICHOLAS S. EYRE
MICHAEL R. BEARD
School of Molecular and Biomedical Science
University of Adelaide and
Centre for Cancer Biology
Adelaide, Australia
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